These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 38897061)

  • 1. Tumor associated antigens combined with carbon dots for inducing durable antitumor immunity.
    Liu H; Zhang T; Zheng M; Xie Z
    J Colloid Interface Sci; 2024 Nov; 673():594-606. PubMed ID: 38897061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetically Engineered Cytomembrane Nanovaccines for Cancer Immunotherapy.
    Pan Y; Wu X; Liu L; Zhao C; Zhang J; Yang S; Pan P; Huang Q; Zhao XZ; Tian R; Rao L
    Adv Healthc Mater; 2024 May; 13(13):e2400068. PubMed ID: 38320299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carbon Dots and Tumor Antigen Conjugates as Nanovaccines for Elevated Cancer Immunotherapy.
    Liu H; Xie Z; Zheng M
    Small; 2023 Aug; 19(31):e2206683. PubMed ID: 36978241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Melittin-lipid nanoparticles target to lymph nodes and elicit a systemic anti-tumor immune response.
    Yu X; Dai Y; Zhao Y; Qi S; Liu L; Lu L; Luo Q; Zhang Z
    Nat Commun; 2020 Feb; 11(1):1110. PubMed ID: 32111828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy and Prevention of Cancer by Nanovaccines Loaded with Whole-Cell Components of Tumor Tissues or Cells.
    Ma L; Diao L; Peng Z; Jia Y; Xie H; Li B; Ma J; Zhang M; Cheng L; Ding D; Zhang X; Chen H; Mo F; Jiang H; Xu G; Meng F; Zhong Z; Liu M
    Adv Mater; 2021 Oct; 33(43):e2104849. PubMed ID: 34536044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
    Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
    Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthetic Particles for Cancer Vaccines: Connecting the Inherent Supply Chain.
    Xia Y; Song T; Hu Y; Ma G
    Acc Chem Res; 2020 Oct; 53(10):2068-2080. PubMed ID: 32945648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer Cell Membrane-Coated Adjuvant Nanoparticles with Mannose Modification for Effective Anticancer Vaccination.
    Yang R; Xu J; Xu L; Sun X; Chen Q; Zhao Y; Peng R; Liu Z
    ACS Nano; 2018 Jun; 12(6):5121-5129. PubMed ID: 29771487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lymph-targeted high-density lipoprotein-mimetic nanovaccine for multi-antigenic personalized cancer immunotherapy.
    Liu M; Feng Y; Lu Y; Huang R; Zhang Y; Zhao Y; Mo R
    Sci Adv; 2024 Mar; 10(11):eadk2444. PubMed ID: 38478602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surgical Tumor-Derived Personalized Photothermal Vaccine Formulation for Cancer Immunotherapy.
    Ye X; Liang X; Chen Q; Miao Q; Chen X; Zhang X; Mei L
    ACS Nano; 2019 Mar; 13(3):2956-2968. PubMed ID: 30789699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced antitumor immunity by targeting dendritic cells with tumor cell lysate-loaded chitosan nanoparticles vaccine.
    Shi GN; Zhang CN; Xu R; Niu JF; Song HJ; Zhang XY; Wang WW; Wang YM; Li C; Wei XQ; Kong DL
    Biomaterials; 2017 Jan; 113():191-202. PubMed ID: 27816821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Manganese oxide-constructed multifunctional biomimetic nanovaccine for robust tumor-specific T cell priming and chemodynamic therapy.
    Li T; Chen G; Lin L; Li B; Wang X; Chen Y; Huang W; Cai M; Xiao Z; Shuai X; Zhu K
    Biomaterials; 2024 Sep; 309():122626. PubMed ID: 38795524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Engineered fluorescent carbon dots as promising immune adjuvants to efficiently enhance cancer immunotherapy.
    Luo L; Liu C; He T; Zeng L; Xing J; Xia Y; Pan Y; Gong C; Wu A
    Nanoscale; 2018 Nov; 10(46):22035-22043. PubMed ID: 30452049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acidity-responsive polyphenol-coordinated nanovaccines for improving tumor immunotherapy
    Qiu H; Wang S; Huang R; Liu X; Li L; Liu Z; Wang A; Ji S; Liang H; Jiang BP; Shen XC
    Biomater Sci; 2024 Jun; 12(12):3175-3192. PubMed ID: 38742916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liposomes-coated gold nanocages with antigens and adjuvants targeted delivery to dendritic cells for enhancing antitumor immune response.
    Liang R; Xie J; Li J; Wang K; Liu L; Gao Y; Hussain M; Shen G; Zhu J; Tao J
    Biomaterials; 2017 Dec; 149():41-50. PubMed ID: 28992509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New generation of DNA-based immunotherapy induces a potent immune response and increases the survival in different tumor models.
    Lopes A; Bastiancich C; Bausart M; Ligot S; Lambricht L; Vanvarenberg K; Ucakar B; Gallez B; Préat V; Vandermeulen G
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33795383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploiting Preexisting Immunity to Enhance Oncolytic Cancer Immunotherapy.
    Tähtinen S; Feola S; Capasso C; Laustio N; Groeneveldt C; Ylösmäki EO; Ylösmäki L; Martins B; Fusciello M; Medeot M; Tagliamonte M; Chiaro J; Hamdan F; Peltonen K; Ranki T; Buonaguro L; Cerullo V
    Cancer Res; 2020 Jun; 80(12):2575-2585. PubMed ID: 32107211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Adjuvant of α-Galactosylceramide Presented by Gold Nanoparticles Enhances Antitumor Immune Responses of MUC1 Antigen-Based Tumor Vaccines.
    Liu Y; Wang Z; Yu F; Li M; Zhu H; Wang K; Meng M; Zhao W
    Int J Nanomedicine; 2021; 16():403-420. PubMed ID: 33469292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Highly Enhanced Antitumor Immunity by a Three-Barreled Strategy of the l-Arginine-Promoted Nanovaccine and Gene-Mediated PD-L1 Blockade.
    Hu Y; Lin L; Chen J; Hao K; Zhang S; Guo X; Guo Z; Tian H; Chen X
    ACS Appl Mater Interfaces; 2020 Sep; 12(37):41127-41137. PubMed ID: 32808767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.